ArticleRenal failure2026
Validation study of the antineutrophil cytoplasmic antibody (ANCA) kidney risk score in Japanese patients with ANCA-associated glomerulonephritis.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2018, the Antineutrophil Cytoplasmic Antibody (ANCA) Renal Risk Score (ARRS) was proposed as a prognostic tool for renal outcomes in patients with ANCA-associated glomerulonephritis (AAGN). Subsequently, a revised version of the ANCA Kidney Risk Score (AKRiS) was reported in 2024. Nonetheless, its usefulness in Japanese patients has not yet been evaluated. We retrospectively analyzed 109 patients with biopsy-proven AAGN (mean age, 69 years; 50% male) from 13 institutions in Nagasaki Prefecture between January 1995 and December 2019. The prognostic performance of both the ARRS and AKRiS for end-stage kidney disease was assessed using Kaplan-Meier analysis, log-rank test, and receiver operating characteristic (ROC) curve analysis. Myeloperoxidase-ANCA positivity was observed in 90.8% of patients. Based on the AKRiS, 47, 39, 15, and 8 patients were classified as low-, medium-, high-, and very high-risk, respectively. The median observation period was 863 days (interquartile range 254.5-2034). Both the ARRS and AKRiS groups demonstrated progressively worse renal survival with increasing risk categories (both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.